To curb drug prices, Democrats still seeking a balance Beállítások

[limited]

Democrats are committed to passing legislation this year to curb prescription drug prices, but they're still disagreeing on how to cut costs for patients and taxpayers while preserving profits that lure investors to back potentially promising treatments.

It boils down เกมสล็อต to finding a balance: How big a stick should Medicare have to negotiate prices with pharmaceutical companies?

With hundreds of billions of dollars in potential savings, the stakes are enormous. Medicare spends upward of $200 billion a year on prescription drugs, a category that keeps growing as costly new drugs enter the market. An Alzheimer's medication approved just last week comes with a price of $56,000 a year, for example, and co-payments could skyrocket for patients who use it.

A successful bill would advance a a key plank of President Joe Biden's domestic agenda even as Democrats struggle to make progress on other fronts. Allowing Medicare to negotiate drug prices consistently wins strong public support in opinion polls.

In the House, Speaker Nancy Pelosi, D-Calif., is steering legislation that imposes a steep tax on drugmakers that refuse to deal with Medicare, while using an average of prices in other economically advanced countries as a reference point for fair rates here. Her bill would limit price increases and allow private health plans to receive Medicare's negotiated rates.

In the Senate, Finance Committee Chairman Ron Wyden, D-Ore, is also working to craft legislation. His starting point is a less ambitious bipartisan bill from a previous Congress. It would have limited price increases for drugs already on the market, but not initial prices. It would have capped Medicare recipients' out-of-pocket costs for pharmacy drugs, which is in the Pelosi bill.

Wyden said he personally is convinced that “it’s long past time to give Medicare the authority to negotiate better prices for prescription drugs.” But cajoling enough votes in the Senate is another matter. It's unclear whether Wyden can even count on all the Democrats in the divided chamber or whether any Republicans would sign on.